Feasibility Study of Metformin Therapy in ADPKD

Completed · Phase 2 · Has a placebo group

Conditions studied: Polycystic Kidney, Autosomal Dominant

In brief

This study is being done to determine if treatment with metformin, a drug widely used for the treatment of diabetes type 2, is safe and well tolerated by individuals with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who are not diabetic and who have slightly decreased kidney function. The study will also evaluate the effects of metformin on kidney growth and kidney function.

Key facts

Study ID

NCT02903511

Run by

University of Colorado, Denver

People needed

56

Starts

2016-11-01

Expected to finish

2020-08-17

Last updated by the study team

2021-09-05

Who can join

Age: 30 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Autosomal Dominant Polycystic Kidney Disease and
• An estimated glomerular filtration (GFR) rate of 50-80 ml/min/1.73 m2;
• Subject is able to sign an Informed Consent

You may not qualify if…

• Diabetes mellitus,
• Active infection,
• Congestive heart failure,
• Liver disease,
• Alcohol or substance dependence,
• Cigarette smoking within the last 12 months;
• Females who are pregnant or breast feeding, or
• Are unwilling to use contraception;
• Are unable to undergo magnetic resonance imaging, or
• Have a contraindication to the use of metformin

Where it is running

• University of Colorado Denver, Anschutz Medical Campus — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.